Search results for "Infusions"

showing 10 items of 168 documents

Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis : a comparative study

2009

Aims: We analyze the possible clinical differences between bone jaw exposed areas in ONJ (osteonecrosis of the jaws) and ORN (osteoradionecrosis). Patients and method: Group 1 was composed with 53 ONJ cases and group 2 with 20 ORN cases. In both groups we analyzed, the major size of the exposed bone areas, the number of exposed areas, the location on the jaws and the presence of others associated and severe complications, such as skin fistulas and jaw fractures. We also investigated the possible local aetiology or trigger factor of the lesions. Results: The major size of the bone exposed areas was 2.29±2.02(mean ± std.dev) in group 1 and 2.7±2.9 (mean ± std.dev) in group 2 (p>0.05). The num…

Malemedicine.medical_specialtyOsteoradionecrosismedicine.medical_treatmentDentistryIntravenous bisphosphonatesCerebrospinal fluid fistulamedicineHumansInfusions IntravenousGeneral DentistryDiphosphonatesTrigger factorbusiness.industryOsteonecrosismedicine.disease:CIENCIAS MÉDICAS [UNESCO]SurgeryOsteoradionecrosisOtorhinolaryngologyDental extractionJaw FractureUNESCO::CIENCIAS MÉDICASEtiologyFemaleSurgerybusinessJaw Diseases
researchProduct

High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients.

2008

Peripheral edema is a common feature in populations with advanced cancer, although it is seldom recognized. Diuretics are commonly employed and may show some benefit, but there are insufficient clinical trial data to draw useful conclusions about their clinical use. The aim of this prospective study was to evaluate the efficacy and tolerability of high-dose furosemide and small-volume hypertonic saline solution infusion in reducing leg edema in patients with advanced cancer treated unsuccessfully with diuretics. A prospective study was performed in a consecutive sample of 24 patients admitted to a pain relief and palliative care unit over a period of 18 months. To be eligible to enter the t…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentPeripheral edemaFurosemideEdemaNeoplasmsmedicineEdemaHumansLongitudinal StudiesProspective StudiesDiureticsInfusions IntravenousSalineGeneral NursingAgedAged 80 and overSaline Solution HypertonicLegbusiness.industryFurosemideMiddle AgedHypertonic salineSurgeryAnesthesiology and Pain MedicineTolerabilityAnesthesiaFemaleNeurology (clinical)medicine.symptomDiureticbusinessmedicine.drugJournal of pain and symptom management
researchProduct

Back pain after photodynamic therapy with verteporfin.

2005

Purpose To report the incidence of back pain after photodynamic therapy, which suggests methods for prevention that are related to its pathogenesis. Design Retrospective case series. Methods We retrospectively observed 548 patients who had undergone photodynamic therapy with verteporfin. Results Of 548 patients at the first treatment, 14 patients (2.6%) experienced pain during the infusion. Eleven patients were being treated for age-related macular degeneration; their mean age was 81 years, which significantly differed from the mean age of the overall age-related macular degeneration group ( P = .003). The pain was mild in eight patients, moderate in four patients, and severe in two patient…

Malemedicine.medical_specialtyPorphyrinsmedicine.medical_treatmentPhotodynamic therapyMacular Degenerationback painphotodynamic therapymedicineBack painHumansInfusions IntravenousAgedRetrospective StudiesAged 80 and overPhotosensitizing AgentsMild painSettore MED/30 - Malattie Apparato Visivobusiness.industryIncidence (epidemiology)IncidenceVerteporfinRetrospective cohort studyMacular degenerationMiddle Agedmedicine.diseaseVerteporfinLow back painChoroidal NeovascularizationSurgeryOphthalmologyPhotochemotherapyBack PainMyopia DegenerativeFemalemedicine.symptombusinessmedicine.drugAmerican journal of ophthalmology
researchProduct

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a m…

2006

ABSTRACT Background: Combinations of gemcitabine–oxaliplatin, gemcitabine–5-fluorouracil (5-FU) and 5-FU–oxaliplatin have synergistic activity and nonoverlapping adverse effect profiles. This trial assessed efficacy and safety of the triple combination gemcitabine–oxaliplatin and infusional 5-FU in patients with locally advanced (n = 11) or metastatic (n = 32) pancreatic adenocarcinoma. Patients and methods: A total of 43 eligible patients were treated with intravenous infusions of gemcitabine (900 mg/m2 over 30 min), followed by oxaliplatin (65 mg/m2 over 2 h) and 5-FU (1500 mg/m2 over 24 h) on days 1 and 8 of a 21-day cycle. Results: Among all 43 patients, the tumor response rate was 19% …

Malemedicine.medical_specialtyTime FactorsOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchAdenocarcinomaDeoxycytidineGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLost to follow-upInfusions IntravenousAgedChemotherapyCardiotoxicitybusiness.industryCombination chemotherapyHematologyMiddle AgedGemcitabineChemotherapy regimenGemcitabineSurgeryOxaliplatinOxaliplatinPancreatic NeoplasmsSurvival RateTreatment OutcomeOncologyDisease ProgressionQuality of LifeFemaleFluorouracilbusinessmedicine.drugAnnals of Oncology
researchProduct

Ventilator-Associated Lung Injury Superposed to Oleic Acid Infusion or Surfactant Depletion: Histopathological Characteristics of Two Porcine Models …

2009

<i>Background:</i> The pathophysiological concept of acute lung injury (ALI) in combination with ventilator-associated lung injury (VALI) is still unclear. We characterized the histopathological features of intravenous injection of oleic acid (OAI) and lung lavage (LAV) combined with VALI. <i>Methods:</i> Pigs were randomized to the control, LAV or OAI group and ventilated by pressure-controlled ventilation. Measurements included: haemodynamics, spirometry, blood gas analysis, lung wet-to-dry weight ratio (W/D), total protein content in broncho-alveolar lavage fluid (BALF), and lung pathological description and scoring. <i>Results:</i> Five hours after lu…

Malemedicine.medical_specialtyVentilator-associated lung injurySwineAcute Lung InjuryLung injurychemistry.chemical_compoundPulmonary surfactantmedicineAnimalsHumansInfusions IntravenousTherapeutic IrrigationRespiratory Distress SyndromeLungbusiness.industryPulmonary Surfactantsrespiratory systemmedicine.diseaseRespiration ArtificialPathophysiologyrespiratory tract diseasesDisease Models AnimalOleic acidmedicine.anatomical_structurechemistryAnesthesiaFemaleSurgeryHistopathologybusinessBronchoalveolar Lavage FluidOleic AcidEuropean Surgical Research
researchProduct

Antigen carbohydrate 125 and creatinine on admission for prediction of renal function response following loop diuretic administration in acute heart …

2014

The use of loop diuretics in acute heart failure (AHF) is largely empirical and has been associated with renal function impairment by reducing renal perfusion but also renal improvement by decreasing renal venous congestion. Antigen carbohydrate 125 (CA125) has emerged as a proxy for fluid overload. We sought to evaluate whether the early changes in creatinine (ΔCr) induced by intravenous furosemide doses (ivFD) differ among clinical groups defined by overload status (CA125) and creatinine on admission (Cr).We included 526 consecutive patients admitted for AHF. All patients received intravenous furosemide for the first 48 hours. CA125 and Cr were dichotomized at 35 U/ml and 1.4 mg/dl, respe…

Malemedicine.medical_specialtymedicine.drug_classUrologyRenal functionKidneyCohort Studieschemistry.chemical_compoundPatient AdmissionAntigenSodium Potassium Chloride Symporter InhibitorsPredictive Value of TestsInternal medicinemedicineHumansIn patientInfusions IntravenousAgedAged 80 and overHeart FailureCreatininebusiness.industryFurosemideCarbohydrateLoop diureticMiddle Agedmedicine.diseaseEndocrinologychemistryHeart failureCA-125 AntigenCreatinineAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesInternational journal of cardiology
researchProduct

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refract…

2003

Background Diuretics have been accepted as first-line treatment in refractory congestive heart failure (CHF), but a lack of response to them is a frequent event. A randomized, single-blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory New York Heart Association (NYHA) class IV CHF and a normosodic diet during follow-up. Materials and Methods One hundred seven patients (39 women and 68 men, age range 65-90 years) with refractory CHF (NYHA class IV) of different etiologies, who were unresponsive to high oral doses of furosemide, angiotensin-converting enzyme inhib…

Malemedicine.medical_specialtymedicine.medical_treatmentAdministration OralDrug Administration ScheduleBolus (medicine)FurosemideHeart rateMedicineHumansSingle-Blind MethodDiureticsInfusions IntravenousBlood urea nitrogenAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionDose-Response Relationship Drugbusiness.industryFurosemideSodium Dietarymedicine.diseaseSurvival AnalysisSurgeryTreatment OutcomeHeart failureAnesthesiaQuality of LifeFemaleDiureticCardiology and Cardiovascular MedicinebusinessHyponatremiamedicine.drugFollow-Up StudiesAmerican heart journal
researchProduct

Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases.

1994

A multicenter, randomized Phase 2 study that compared patients, affected by colorectal liver metastases, who received intrahepatic arterial infusion with two different schedules of cisplatin, bolusvs. continuous infusion, and systemic 5-fluorouracil. PURPOSE: The aim of this study was to validate results of a previous Phase 2 trial on bolus cisplatin intrahepatic arterial infusion, which reported a 47 percent response rate and a 32 percent 4-year survival rate for Gennari's Stage 2 patients, with a high rate of neurologic, gastrointestinal, and hematologic toxicity. METHODS: One hundred nine patients were randomized in a Phase 2 study to receive cisplatin intrahepatic arterial infusion (24 …

Malemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchGastroenterologyBolus (medicine)Hepatic arterial infusionHepatic ArteryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialInfusions IntravenousSurvival rateCisplatinChemotherapybusiness.industryLiver NeoplasmsGastroenterologyGeneral MedicineMiddle AgedSurvival RateInjections Intra-ArterialFluorouracilAnesthesiaToxicityFemaleFluorouracilCisplatinbusinessColorectal Neoplasmsmedicine.drugDiseases of the colon and rectum
researchProduct

Combined medical and mechanical recanalization in acute myocardial infarction

1985

A technique of combined medical and mechanical recanalization was employed in 96 patients with acute transmural myocardial infarction. The mean time between onset of symptoms and admission to hospital was 170 +/- 65 min (X +/- SD). After 10 +/- 16 min, 250,000 U streptokinase was administered intravenously for 20 min. Intracoronary thrombolysis was commenced within 38 +/- 14 min. First coronary angiograms demonstrated reperfusion, an open vessel in 25/96 patients (26%). In 15/71 patients (21%) reperfusion occurred during thrombolysis therapy, before mechanical recanalization could be performed. Recanalization was achieved mechanically in 37/71 patients (52%) with occluded coronary vessels. …

Malemedicine.medical_specialtymedicine.medical_treatmentStreptokinaseMyocardial InfarctionCoronary DiseaseAnterior myocardial infarctionElectrocardiographyRecurrenceCoronary CirculationInternal medicinemedicineHumansInfusions ParenteralStreptokinaseMyocardial infarctionAgedChemotherapybusiness.industryHemodynamicsArrhythmias CardiacStroke VolumeThrombolysisMiddle Agedmedicine.diseaseCombined Modality TherapyMyocardial ContractionPeripheralCoronary vesselCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty Balloonmedicine.drugIntracoronary thrombolysisCatheterization and Cardiovascular Diagnosis
researchProduct

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

2021

Abstract Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% o…

Malemedicine.medical_specialtyustekinumabVedolizumab03 medical and health sciences0302 clinical medicineremissionColitis ulcerosaInternal medicineUstekinumabHumansMedicineProspective StudiesRegistriesInfusions IntravenousAdverse effectreal-world evidenceAcademicSubjects/MED00260ulcerative colitisTofacitinibresponsebiologybusiness.industryRemission InductionC-reactive proteinGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuation030220 oncology & carcinogenesisCohortbiology.proteindurabilityOriginal ArticleColitis UlcerativeFemaleMonoclonal antibodies030211 gastroenterology & hepatologyUstekinumabbusinessAnticossos monoclonalsmedicine.drug
researchProduct